Chiasma announces publication of octreotide capsules Stage III study results in JCEM Chiasma Inc.

These new results using a daily oral medication are a significant advance for people with acromegaly. The security profile of octreotide capsules is apparently in keeping with the known profile of injectable octreotide formulations, excluding injection site reactions, stated Gary Patou, M.D., Chiasma's senior medical advisor. Actually, in this study, we found the incidence of adverse occasions significantly decrease as time passes. Chiasma is pleased with the results of this Phase III study being published in the current issue of JCEM, as they show the potential utility of octreotide capsules in the treatment of adults with acromegaly, said Roni Mamluk, Ph.D., Chiasma's chief executive officer. If accepted, octreotide capsules would be the first oral somatostatin analog, and would give people with acromegaly a unique alternative to chronic shots that are the current regular treatment for this lifelong disease.The U.S. Meals and Drug Administration granted orphan drug position to Multikine in the neoadjuvant therapy of individuals with squamous cell carcinoma of the top and neck.

Covering characterisation of polymer-coated cardiovascular stents Covering characterisation of polymer-coated cardiovascular stents offers been undertaken utilising ToFSIMS, DSIMS and 3DP. Time-of-Air travel Secondary Ion Mass Spectrometry provides detailed molecular details from the outer surface area of a stent to research the molecular make-up of the contact point between stent and web host. Contamination on the top of stents may also be investigated by ToFSIMS providing spectra and pictures of the top i.e.